Long et al. extensively studied the properties of a novel apigenin-piperazine hybrid (5), according to QSAR studies (Figure 3), that exhibited low nanomolar inhibitory effect against PARP-1 [23] and moderate antitumor activity against A549 and SKOV-3 xenografted mice (50 mg/kg for 12 days, relative tumor volume = 0.74 compared to 2.12 of Olaparib, a PARP-1 inhibitor). The gene discussed is PARP1; the disease is neoplasm.